PharmaCyte Biotech Gross Profit

PharmaCyte Biotech posts a gross profit of $0 as of April 2026. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PharmaCyte Biotech's gross profit was $0. The latest reading is $0 (period ending April 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $67B is typical. PharmaCyte Biotech's $0 is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of PharmaCyte Biotech's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PMCB's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; PharmaCyte Biotech's other metric pages and overview cover the third.